Who are Folferi and celecoxib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folferi-and-celecoxib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Folferi and celecoxib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Folferi and celecoxib (Folferi and celecoxib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with COX-2 inhibitor. Area: Oncology.

marketed Chemotherapy combination with COX-2 inhibitor Topoisomerase I (irinotecan), thymidylate synthase (fluorouracil), COX-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Folferi and celecoxib (Folferi and celecoxib) — Sherief Abd-Elsalam. FOLFIRI chemotherapy combined with celecoxib inhibits tumor cell division through fluorouracil and irinotecan while reducing inflammation via COX-2 inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Folferi and celecoxib TARGET	Folferi and celecoxib	Sherief Abd-Elsalam	marketed	Chemotherapy combination with COX-2 inhibitor	Topoisomerase I (irinotecan), thymidylate synthase (fluorouracil), COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with COX-2 inhibitor class)

Sherief Abd-Elsalam · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Folferi and celecoxib — Competitive Intelligence Brief. https://druglandscape.com/ci/folferi-and-celecoxib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab